ArticleBMC infectious diseases2025
High prevalence of antibiotic resistant Campylobacter among patients attending clinical settings in Kigali, Rwanda.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThermophilic Campylobacter species are important causes of human gastroenteritis and inappropriate use of antimicrobials has led to the emergence of antimicrobial resistance (AMR). In Rwanda, data is limited on the prevalence and AMR carriage rate of Campylobacter strains. This study aimed at assessing the prevalence and antimicrobial susceptibility profiles of Campylobacter species among isolates obtained from different clinical settings in Kigali city, Rwanda.
methodsThis cross-sectional study used a purposive sampling method to collect 385 stool samples from consenting patients attending the Microbiology Department at Kigali University Teaching Hospital (CHUK), Nyarugenge District Hospital, Muhima and Biryogo Health Centers (HC). Campylobacter species were isolated using culture and characterized with biochemical tests and multiplex Polymerase Chain Reaction (PCR) for species confirmation. Antimicrobial susceptibility testing (AST) with six antimicrobials [ciprofloxacin (CIP), tetracycline (TET), chloramphenicol (CHL), streptomycin (STR), erythromycin (ERY), and gentamicin (GEN)] was carried out by using Kirby-Bauer disk diffusion.
resultsThe overall prevalence of Campylobacter spp. was 7.0% (27/385) and the highest prevalence of 77.8% (21/27) was recorded at Biryogo HC. The prevalence of C. jejuni and C. coli were 92.6% (25/27) and 7.4% (2/27), respectively. Infection was significantly associated with diarrhea (p < 0.0001). Campylobacter isolates showed high resistance to STR (85.2%, 23/27), followed by ERY (66.7%, 18/27), and CIP (37.1%, 10/27). The isolates were sensitive to CHL at 88.9% (24/27), TET at 66.7% (18/27), and GEN at 66.7% (18/27).
conclusionThe prevalence of campylobacteriosis in Kigali City is not negligible and is associated with diarrhea. Campylobacter strains isolated from clinical settings were resistant to commonly used antimicrobials. Larger studies will provide insights into the national status of Campylobacter-related AMR. Routine monitoring of antimicrobial use is recommended to mitigate this public health threat. Molecular analyses of resistant strains are warranted to characterize the genomic drive of antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.